SCOTTSDALE, Ariz., April 29, 2025 – SimonMed Imaging (“SimonMed”), one of the largest outpatient medical imaging providers in the U.S., today announced the launch of DEXA + TBS (Trabecular Bone Score), a next-generation bone health screening that combines bone density and bone quality analysis—setting a new standard of care in osteoporosis detection and fracture prevention.

The announcement comes ahead of National Osteoporosis Awareness and Prevention Month in May. Osteoporosis, often called a "silent disease," weakens bones without warning—until a fracture happens. Each year, osteoporosis causes an estimated 2 million fractures in the U.S., yet nearly 80% of older adults who suffer fractures are never tested or treated, according to the Bone Health and Osteoporosis Foundation. Early detection is critical to preventing the serious, life-altering impacts of untreated bone loss.

Developed in partnership with Medimaps Group, DEXA + TBS integrates FDA-approved software into standard DEXA scans to measure both bone mineral density (BMD) and trabecular bone score (TBS), which evaluates bone microarchitecture. This dual analysis allows clinicians to identify up to 30% more patients at high risk of fracture, even when bone density appears normal.
“Osteoporosis is often diagnosed too late—after a fracture has already impacted quality of life,” said Dr. John Simon, CEO and Founder of SimonMed Imaging. “With DEXA + TBS, we’re giving patients and providers a more complete picture of bone health so they can make proactive decisions earlier, to prevent and treat the disease.”

Osteoporosis affects millions—impacting 1 in 2 women and 1 in 4 men over age 50 with a lifetime risk of fracture. Early detection is critical.

“Our partnership with SimonMed is about shifting from reactive to proactive care,” said Univ.-Prof. Dr. Didier Hans, CEO and Co-founder of Medimaps Group. “By expanding access to advanced diagnostics like TBS, we enable smarter, earlier decisions that prevent fractures and improve outcomes.”

DEXA + TBS is now available at over 80 SimonMed locations equipped with DEXA technology, furthering the company’s mission to make cutting-edge diagnostics both affordable and accessible.

SimonMed continues to lead in AI-powered imaging across multiple specialties— including breast cancer, brain health, and now, bone health. Learn more at simonmed.com.


About SimonMed
Headquartered in Scottsdale, Arizona, SimonMed is one of the largest outpatient medical imaging providers and radiology practices in the United States. SimonMed has approximately 170 sites across 11 states and over 200 subspecialty-trained radiologists. SimonMed offers the full modality of diagnostic scans, including 3T MRI, CT, ultrasound, 3-D mammography, PET/CT, nuclear medicine, DEXA, X-rays, among others. The company uses the newest, most advanced, diagnostic imaging technologies while maintaining affordability and accessibility. SimonMed is a worldwide leader in the clinical use of AI to improve diagnoses with one of the largest global deployments to enhance early breast cancer detection and in the evaluation of brain disorders. Through its simonONE division, SimonMed is also at the forefront of personalized imaging for the early diagnosis and treatment of disease. For more information, visit simonone.com and simonmed.com.


About Medimaps Group
Medimaps Group is a Swiss-based company developing and marketing software as a medical device solutions. Our medical imaging software applications are developed with the patient in mind, and are based on patented multi-purpose technology with artificial intelligence capabilities, providing healthcare solutions that fit seamlessly into the workflow. Our lead product TBS iNsight™ (Osteo) has been used for years in clinical practice worldwide in the field of osteoporosis, and is established as the gold standard for bone texture assessment in clinical practice. Learn more at
https://www.medimaps.ai

US Press Room Homepage